General
Preferred name
ROTIGOTINE
Synonyms
Rotigotine hydrochloride ()
N-0923 D7 Hydrochloride ()
Rotigotine (D7 Hydrochloride) ()
N-0923 Hydrochloride ()
N-0923 ()
N-0924 ()
Rotigotine HCl ()
Rotigotine (Hydrochloride) ()
Rotigotine ()
Neupro ()
Rotigitine ()
N-0437 ()
(-)-N 0437 ()
N-0923 (Hydrochloride) ()
Leganto ()
SPM-962 ()
SPM 962 ()
P&D ID
PD010675
CAS
125572-93-2
99755-59-6
Tags
available
drug
drug candidate
biased GPCR ligand
Approved by
FDA
First approval
2007
Drug Status
approved
withdrawn
Drug indication
Parkinson disease
Restless legs syndrome
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION Bioavailability varies depending on the application site. Differences in bioavailability were very small between the abdomen and hip (<1%). In contrast, the shoulder and thigh had a very large different in measured bioavailability (46%), with the shoulder showing the higher value. ; Tmax, 8 mg dose = 15 - 18 hours (it take approximately 3 hours until rotigotine reaches detectable levels in the plasma). The peak concentration cannot be observered. Steady state is reached in 2-3 days.
DESCRIPTION Rotigotine is a non-ergoline type, dopamine receptor agonist drug. At clinical doses rotigotine acts somewhat selectively for D1-like (D1, D5) and D2-like (D2, D3, D4) receptors. α2B-adrenergic and 5-HT1A activity may also provide some clinical benefit. (GtoPdb)
DESCRIPTION Rotigotine is a dopamine agonist of the non-ergoline class of medications indicated for the treatment of Parkinson's disease (PD) and Willis-Ekbom Disease. (BOC Sciences Bioactive Compounds)
DESCRIPTION NPY Y2 receptor antagonist (Tocris Bioactive Compound Library)
DESCRIPTION Dopamine D2/D3 agonist (Tocriscreen Plus)
Compound Sets
29
AdooQ Bioactive Compound Library
A11553
A11118
Axon Medchem Screening Library
1040
BiasDB
Rotigotine
BOC Sciences Bioactive Compounds
rotigotine-cas-99755-59-6-item-84-80599
Cayman Chemical Bioactives
20246
ChEMBL Approved Drugs
CHEMBL1303
ChEMBL Drugs
CHEMBL1303
Concise Guide to Pharmacology 2017/18
941
Concise Guide to Pharmacology 2019/20
941
Concise Guide to Pharmacology 2021/22
941
Concise Guide to Pharmacology 2023/24
941
Drug Repurposing Hub
DrugBank
DB05271
DrugBank Approved Drugs
DB05271
DrugCentral
2407
DrugCentral Approved Drugs
2407
DrugMAP
DMHEAB1
DMT0DW4
Guide to Pharmacology
941
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1303
MedChem Express Bioactive Compound Library
HY-75502
HY-A0007
NCATS Inxight Approved Drugs
87T4T8BO2E
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
rotigotine
TargetMol Bioactive Compound Library
T21446
Tocris Bioactive Compound Library
3896
Tocriscreen Plus
3896
Withdrawn 2.0
1429
External IDs
54
Properties
(calculated by RDKit )
Molecular Weight
315.17
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
2
cLogP
4.27
TPSA
23.47
Fraction CSP3
0.47
Chiral centers
1.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
7-TM Receptors
Target
Dopamine Receptor
D1
D2
D3
D4
D5
??2B-adrenergic receptor
ADRA2B, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A
DA agonist
5-HT Receptor
Adrenergic Receptor
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Primary Target
D2 Receptors
MOA
Agonist
Dopamine Receptor agonist
Indication
Parkinson's Disease, restless leg syndrome
ATC
N04BC09
Source data